Search

The effect on weight reduction of fish oil combined with food restriction in comparison with that of beef tallow was investigated in high-fat diet-induced obese KKAy mice. Although the reduction of body and white adipose tissue weight was similar in the two groups, fish oil increased adiponectin levels in the plasma, improved dyslipidemia accompanied by suppression of lipid synthesis in the liver when compared with beef tallow.

Trigonella foenum-graecum L. (fenugreek) has been described earlier and its use in ancient medicinal practice is well known. The hypoglycemic effects of fenugreek have been studied in many animal models and diabetic patients. The purpose of this study was to examine the preventive efficiency of dietary fenugreek on diet-induced metabolic diseases in rats. The diets used in this study were a standard diet, a high-fat high-sucrose (HFS) diet, and a HFS diet containing 0.5 g/kg b. w./day fenugreek based on the modified version of the AIN-93G purified diet, for 12 weeks, respectively. The rats fed the HFS diet containing fenugreek showed significantly lower fasting insulin levels and HOMA-IR than the rats fed the HFS diet. Therefore, fenugreek improved insulin sensitivity in rats. The triglyceride and total cholesterol levels in the plasma were significantly lower in the fenugreek-administered group. Moreover, distinct reductions of triglyceride, total cholesterol, free fatty acid, and phospholipid levels in the liver were found in the rats fed the HFS diet containing fenugreek. These results suggest that fenugreek enhanced insulin sensitivity at least partly by improving lipid metabolism disorders in the plasma and the liver in the rats induced by the HFS diet.

The components bringing the effects of fish oil on glucose and lipid metabolism are unclear. We used hydrogenated fish oil, which has saturated fatty acids with the same carbon chain lengths as the unsaturated fatty acids in fish oil, to clarify the functions of these unsaturated fatty acids on the improvements in lipid and glucose metabolism in mice. Mice divided into 3 groups were fed different diets: fish oil diet (FO), hydrogenated fish oil diet (HFO), and soybean oil diet (SBO) as a control. Body weight gain and white adipose tissue weight in the HFO and FO groups were significantly decreased compared with those in the SBO group. However, in the HFO group, the triglyceride (TG) levels in plasma were significantly decreased, while the lipids levels in the liver were remarkably increased compared with those in the FO group. Regarding the fatty acid composition in the liver and white adipose tissue in the HFO group, in parallel with the up-regulation of stearoyl-CoA desaturase 1 mRNA, relative amounts of C16 : 1 and C18 : 1 were significantly increased. By contrast, blood glucose levels in the oral glucose tolerance test had not deteriorated in the HFO group. Our results indicate that unsaturated fatty acids in the FO diet decrease lipid levels in the liver and maintain the balance of lipid levels in plasma, liver and white adipose tissue; in addition, in the HFO group, C16 : 1 and C18 : 1 synthesized in the liver and white adipose tissue may improve glucose tolerance and lipid metabolism.

香辛料の一種であるフェヌグリーク (Trigonella foenum-graecum L.) の生活習慣病予防効果を検討した。標準食 (STD) および高脂肪・高ショ糖食 (HFS) の2種類の実験食を作成し, それぞれの実験食にフェヌグリーク添加群を加えて計4群とし, 正常なSD系ラットに摂食させた。HFSではフェヌグリーク添加によって, 体重増加量, エネルギー効率比および精巣周囲白色脂肪組織重量は減少した。また, 肝臓中の総コレステロール量も減少し, 糞中への総胆汁酸排泄量が増加した。しかしながら, 耐糖能に関してはフェヌグリーク添加による大きな影響はみられなかった。以上のことから, フェヌグリークは食餌中脂質の糞中への排泄を促進することによって, 肝臓および白色脂肪組織への脂肪蓄積を抑制し, その結果として体重増加を抑制することが推察された。

We investigated whether oral administration of palmitoleate ameliorates disorders of lipid metabolism to clarify the effects of one of the components of fish oil. Lipid levels in the liver and plasma were significantly decreased by palmitoleate and by EPA administration. These results suggest that palmitoleate, in addition to EPA, plays a role in the regulation of lipid metabolism by fish oil.

Background: Various therapeutic effects of fenugreek (Trigonella foenum-graecum L.) on metabolic disorders have been reported. However, the bitterness of fenugreek makes it hard for humans to eat sufficient doses of it for achieving therapeutic effects. Fenugreek contains bitter saponins such as protodioscin. Fenugreek with reduced bitterness (FRB) is prepared by treating fenugreek with beta-glucosidase. This study has been undertaken to evaluate the effects of FRB on metabolic disorders in rats., Open Access http://www.lipidworld.com/content/11/1/58 ? 2012 Muraki et al.; licensee BioMed Central Ltd.

BackgroundWe previously reported that fenugreek (Trigonella foenum-graecum L.) improved diet-induced metabolic disorders in rats. The purpose of the present study was to examine the dose-dependent effects, safety and tolerability of fenugreek. MethodsThe diets used in this study were the high-fat high-sucrose diet (HFS; lard 50%kcal, sucrose 25%kcal) as a control (Ctrl group) or the HFS containing 0.25% (VL group), 1.25% (L group), 2.50% (M group), 5.00% (H group) or 12.30% (VH group) fenugreek based on the modified version of the AIN-93G purified diet. ResultsFenugreek dose-dependently reduced the hepatic triglyceride and total cholesterol levels. Fenugreek also dose-dependently increased the excretion of cholesterol and total bile acids into the feces. However, the glucose tolerance showed no significant change by fenugreek administration. The VL and L groups did not significantly change triglyceride or total cholesterol levels in the liver. The VL group showed no increase in excretion of triglyceride, total cholesterol or bile acids in the feces. The VH group showed appetite reduction and diarrhea, while no adverse effect or symptoms were observed in the M group. ConclusionThese results suggest that fenugreek inhibited lipid accumulation in the liver by increasing the lipid excretion in the feces. The effective, safe and tolerable dose of fenugreek was found to be around 2.50% (w/w)., Open Access http://www.lipidworld.com/content/10/1/240 (6p.) ? 2011 Muraki et al.; licensee BioMed Central Ltd.